Effects of Ulinastatin on Severe Infection with Systemic Inflammatory Response Syndrome in Elderly Patients

Objective To evaluate the effects of ulinastatin on the prognosis and inflammatory mediators in elderly patients with severe infection and systemic inflammatory response syndrome(SISR).Methods Forty elderly patients with severe infection and SISR were randomly divided into two groups,with 20 patients in each group.The control group received symptomatic treatment.On the basis of symptomatic treatment,the treatment group was given micropump intravenous injection of ulinastatin(300 000 U)once every 12 hours for 7 days.The length of hospital stay,effective rate and mortality rate were compared between the two groups.In addition,fasting venous blood samples were drawn before and 3 and 7 days after treatment for the determination of serum levels of high-sensitivity c-reactive protein(hs-CRP)and tumor necrosis factor(TNF-α).Results Compared with control group,ulinastatin treatment decreased the hospital stay and mortality rate,and increased the effective rate(all P 0.05).After treatment,serum hs-CRP and TNF-α levels were significantly reduced in treatment group(all P0.05),but were not improved in control group.The differences in hs-CRP and TNF-α levels were significant between the two groups(all P 0.05).Conclusion Ulinastatin treatment can inhibit the invasion of inflammatory mediators,improve prognosis and reduce mortality in elderly patients with severe infection and SISR.